2015
Radiation therapy in the locoregional treatment of triple-negative breast cancer
Moran MS. Radiation therapy in the locoregional treatment of triple-negative breast cancer. The Lancet Oncology 2015, 16: e113-e122. PMID: 25752562, DOI: 10.1016/s1470-2045(14)71104-0.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorDecision Support TechniquesDose Fractionation, RadiationFemaleGenetic Predisposition to DiseaseHumansMastectomyNeoplasm Recurrence, LocalPatient SelectionPhenotypePredictive Value of TestsRadiation ToleranceRadiotherapy, AdjuvantRisk AssessmentRisk FactorsTreatment OutcomeTriple Negative Breast Neoplasms
2014
Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?
Moran MS. Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making? American Society Of Clinical Oncology Educational Book 2014, e32-6. PMID: 24857120, DOI: 10.14694/edbook_am.2014.34.e32.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerLocal-regional relapseBreast cancer therapySporadic triple-negative breast cancerBreast cancerEarly-stage triple-negative breast cancerYounger ageAggressive biologic characteristicsBreast conservation approachHER2-positive subgroupContralateral breast cancerWhole breast irradiationDefinitive treatment strategyNegative breast cancer subtypeHypothesis-generating dataPartial breast irradiationBreast cancer subtypesBRCA1 mutation carriersSystemic chemotherapyAdvanced diseaseRandomized trialsGuideline recommendationsLuminal tumorsBreast irradiationTNBC subtypes
2011
ACR Appropriateness Criteria® Ductal Carcinoma in Situ
Moran MS, Bai HX, Harris EE, Arthur DW, Bailey L, Bellon JR, Carey L, Goyal S, Halyard MY, Horst KC, MacDonald SM, Haffty BG. ACR Appropriateness Criteria® Ductal Carcinoma in Situ. The Breast Journal 2011, 18: 8-15. PMID: 22107336, DOI: 10.1111/j.1524-4741.2011.01197.x.Peer-Reviewed Original ResearchConceptsWhole breast radiationDuctal carcinomaAppropriateness CriteriaMultiple phase III studiesAppropriateness of imagingPhase III studyACR Appropriateness CriteriaExpert panelRadiology Appropriateness CriteriaEvidence-based guidelinesMultidisciplinary expert panelOmission of radiationPartial breast radiationSpecific clinical conditionsCurrent medical literatureNon-invasive tumorsInvasive relapseBreast radiationLimited diseaseIII studyPeer-reviewed journalsLocal recurrenceAppropriate patientsTumor bedClinical guidelines
2008
Long‐term outcomes and clinicopathologic differences of African‐American versus white patients treated with breast conservation therapy for early‐stage breast cancer
Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG. Long‐term outcomes and clinicopathologic differences of African‐American versus white patients treated with breast conservation therapy for early‐stage breast cancer. Cancer 2008, 113: 2565-2574. PMID: 18816610, DOI: 10.1002/cncr.23881.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, MucinousAdultAntineoplastic AgentsBlack or African AmericanBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCohort StudiesCombined Modality TherapyFemaleFollow-Up StudiesHumansLymph NodesLymphatic MetastasisMastectomyNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapy DosageSurvival RateTreatment OutcomeWhite PeopleConceptsBreast conservation therapyLymph node recurrenceAA patientsWhite patientsAA womenNode recurrenceConservation therapyClinicopathologic differencesEarly-stage breast cancerChemotherapy/radiotherapyEarly-stage diseaseSurgical margin statusLong-term outcomesP53 expression statusBreast recurrenceOverall survivalIndependent predictorsLocal recurrenceLymph nodesMargin statusClinicopathologic featuresDistant metastasisN classificationMore estrogenBreast cancer